Toulouse

• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• Evaluation of the Efficacy of 3-month Continuous Extended Treatment With Azithromycin in Idiopathic Purulent Oedematous Sinusitis in Adults: … Ended recruitment
  2024-517239-33-00 5 2022-10-06 Ear, nose and throat diseases
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U … Ended recruitment
  2023-504194-21-00 5 2022-09-13 PD-L1 Positive Metastatic Triple-Negative Breast Cancer
• A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL Ended recruitment
  2023-504187-42-00 1 2022-09-12 Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable … Ended recruitment
  2023-504195-14-00 5 2022-08-31 PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
• A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NP … Ended recruitment
  2023-506582-58-00 3 2022-07-21 Acute Myeloid Leukemia
• A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants wit … Ended recruitment
  2022-502681-24-00 3 2022-06-22 Relapsed or Refractory Multiple Myeloma
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Myelin Oligodendrocyte Gly … Ended recruitment
  2023-507196-22-00 5 2022-06-20 Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD
• A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and n … Ended recruitment
  2024-512799-36-00 3 2022-06-16 head and neck squamous cell carcinoma (HNSCC)
• A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati … Ended recruitment
  2023-503999-24-00 5 2022-06-01 Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
• IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot … Ended recruitment
  2023-510387-13-00 4 2022-05-18 advanced ALK-positive non-small cell lung cancer
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and … Ended recruitment
  2024-516403-16-00 5 2022-04-07 Adult patients with immune thrombocytopenia (ITP) with mild to severe
• Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended recruitment
  2023-503517-30-00 5 2022-04-01 Extensive-stage small-cell lung cancer
• A study to assess the Safety, Tolerability, Pharmacokinetics and Anti tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lun … Ended recruitment
  2024-512127-36-00 9 2022-03-31 Non-Small Cell Lung Cancer
• PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION ( … Ended recruitment
  2024-515037-15-00 4 2022-03-02 PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATI
• A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with I … Ended recruitment
  2024-515617-18-00 1 2022-02-14 Advanced clear cell renal cell carcinoma (ccRCC), non-clear cell renal
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509372-41-00 5 2022-01-30 Multiple Sclerosis
• A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profiles of CGT9486 in subjects with Advanced Systemic Mastocy … Ended recruitment
  2024-511407-42-00 4 2022-01-10 Advanced Systemic Mastocytosis
• OASIS II - A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated ma … Ended recruitment
  2024-512634-15-00 9 2022-01-05 Patients with untreated mantle cell lymphoma
• A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma Ended recruitment
  2023-503620-60-00 3 2021-12-22 multiple myeloma
• A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for locally advanced/metastatic Non-S … Ended recruitment
  2023-503674-20-00 5 2021-12-17 Unresectable, locally advanced, or metastatic Non-Small Cell Lung Canc

Showing 433–456 of 642 trials